SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-002398
Filing Date
2023-01-05
Accepted
2023-01-05 16:13:04
Documents
12
Period of Report
2022-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d405031d8k.htm   iXBRL 8-K 28731
  Complete submission text file 0001193125-23-002398.txt   154622

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20221230.xsd EX-101.SCH 2835
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20221230_lab.xml EX-101.LAB 18757
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20221230_pre.xml EX-101.PRE 11700
6 EXTRACTED XBRL INSTANCE DOCUMENT d405031d8k_htm.xml XML 3484
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 23511432
SIC: 2834 Pharmaceutical Preparations